Related references
Note: Only part of the references are listed.Current strategies for the discovery and bioconjugation of smaller, targetable drug conjugates tailored for solid tumor therapy
Mahendra P. Deonarain et al.
EXPERT OPINION ON DRUG DISCOVERY (2021)
Directed evolution methods for overcoming trade-offs between protein activity and stability
Samuel D. Stimple et al.
AICHE JOURNAL (2020)
Miniproteins as a Powerful Modality in Drug Development
Zachary R. Crook et al.
TRENDS IN BIOCHEMICAL SCIENCES (2020)
Development and Differentiation in Monobodies Based on the Fibronectin Type 3 Domain
Peter G. Chandler et al.
CELLS (2020)
Design Strategy to Create Antibody Mimetics Harbouring Immobilised Complementarity Determining Region Peptides for Practical Use
Tetsuya Kadonosono et al.
SCIENTIFIC REPORTS (2020)
Reconstitution of an Anti-HER2 Antibody Paratope by Grafting Dual CDR-Derived Peptides onto a Small Protein Scaffold
Kyra See et al.
BIOTECHNOLOGY JOURNAL (2020)
Spectroscopic Evidence of the Salt-Induced Conformational Change around the Localized Electric Charges on the Protein Surface of Fibronectin Type III
Chikashi Ota et al.
LANGMUIR (2020)
Selection enhances protein evolvability by increasing mutational robustness and foldability
Jia Zheng et al.
SCIENCE (2020)
Integrated computational and experimental design of a monobody targeting PDL1
Reed E. Harrison et al.
CANCER RESEARCH (2020)
Tumor-targeted knockdown of KRAS mutants with novel Centyrin:siRNA conjugates
Russell C. Addis et al.
CANCER RESEARCH (2020)
Enhancing bioactivity, physicochemical, and pharmacokinetic properties of a nano-sized, anti-VEGFR2 Adnectin, through PASylation technology
Safieh Aghaabdollahian et al.
SCIENTIFIC REPORTS (2019)
Protein engineering: the potential of remote mutations
Matthew Wilding et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2019)
Consensus sequence design as a general strategy to create hyperstable, biologically active proteins
Matt Sternke et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity
Jodi L. Karnell et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Advances in liquid formulations of parenteral therapeutic proteins
Robert J. Falconer
BIOTECHNOLOGY ADVANCES (2019)
SAFETY, TOLERABILITY AND LDL-C REDUCTION WITH A NOVEL ANTI-PCSK9 RECOMBINANT FUSION PROTEIN (LIB003): RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY
E. Stein et al.
ATHEROSCLEROSIS (2019)
GSK3732394: a Multi-specific Inhibitor of HIV Entry
David Wensel et al.
JOURNAL OF VIROLOGY (2019)
A Novel Engineered Small Protein for Positron Emission Tomography Imaging of Human Programmed Death Ligand-1: Validation in Mouse Models and Human Cancer Tissues
Arutselvan Natarajan et al.
CLINICAL CANCER RESEARCH (2019)
ABX9xx: A bispecific centyrin that synergizes to attenuate intracellular signaling in Met/EGFR positive tumors
Russ Addis et al.
CANCER RESEARCH (2019)
Principles of Protein Stability and Their Application in Computational Design
Adi Goldenzweig et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 87 (2018)
The direction of protein evolution is destined by the stability
Natsuko Ota et al.
BIOCHIMIE (2018)
Conformational dynamics and enzyme evolution
Dusan Petrovic et al.
JOURNAL OF THE ROYAL SOCIETY INTERFACE (2018)
Clinical trial of P-BCMA-101 T stem cell memory (Tscm) CAR-T cells in relapsed/refractory (r/r) multiple myeloma (MM)
Tara K. Gregory et al.
CANCER RESEARCH (2018)
Synthetic (10)FN3-based mono- and bivalent inhibitors of MDM2/X function
S. -Y. Lau et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2018)
Role of Buffers in Protein Formulations
Teddy J. Zbacnik et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Biophysical properties of the clinical-stage antibody landscape
Tushar Jain et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Circumventing the stability-function trade-off in an engineered FN3 domain
Benjamin T. Porebski et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2016)
Consensus protein design
Benjamin T. Porebski et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2016)
Engineering long shelf life multilayer biologically active surfaces on microfluidic devices for point of care applications
Waseem Asghar et al.
SCIENTIFIC REPORTS (2016)
Smoothing a rugged protein folding landscape by sequence-based redesign
Benjamin T. Porebski et al.
SCIENTIFIC REPORTS (2016)
Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and Therapy
Andreas Plueckthun
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 55 (2015)
Challenges and opportunities for non-antibody scaffold drugs
Rodrigo Vazquez-Lombardi et al.
DRUG DISCOVERY TODAY (2015)
Tolerability of hypertonic injectables
Wei Wang
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2015)
Controlling protein stability: Mechanisms revealed using formulations of arginine, glycine and guanidinium HCl with three globular proteins
Lauren Platts et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2015)
Developability Assessment During the Selection of Novel Therapeutic Antibodies
Alexander Jarasch et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Structural and dynamic properties that govern the stability of an engineered fibronectin type III domain
Benjamin T. Porebski et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2015)
Adnectin-Targeted Inhibitors: Rationale and Results
Esha Sachdev et al.
CURRENT ONCOLOGY REPORTS (2015)
Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma
David Schiff et al.
INVESTIGATIONAL NEW DRUGS (2015)
Effect of Polysorbate 80 Concentration on Thermal and Photostability of a Monoclonal Antibody
Meera Agarkhed et al.
AAPS PHARMSCITECH (2013)
Anti-VEGFR2 and anti-IGF-1R-Adnectins inhibit Ewing's sarcoma A673-xenograft growth and normalize tumor vascular architecture
Maximilian Ackermann et al.
ANGIOGENESIS (2012)
CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy
J. Dawn Waters et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin
Anthony W. Tolcher et al.
CLINICAL CANCER RESEARCH (2011)
Non-immunoglobulin based protein scaffolds
John Lofblom et al.
CURRENT OPINION IN BIOTECHNOLOGY (2011)
Stabilization of a monoclonal antibody during purification and formulation by addition of basic amino acid excipients
Robert J. Falconer et al.
JOURNAL OF CHEMICAL TECHNOLOGY AND BIOTECHNOLOGY (2011)
Adnectins: engineered target-binding protein therapeutics
D. Lipovsek
PROTEIN ENGINEERING DESIGN & SELECTION (2011)
Interaction of Arginine with Proteins and the Mechanism by Which It Inhibits Aggregation
Diwakar Shukla et al.
JOURNAL OF PHYSICAL CHEMISTRY B (2010)
Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2
Roni Mamluk et al.
MABS (2010)
Folding of beta-sandwich proteins: Three-state transition of a fibronectin type III module
Ernesto Cota et al.
PROTEIN SCIENCE (2010)
Stability effects of mutations and protein evolvability
Nobuhiko Tokuriki et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2009)
Recent trends in stabilising peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients
Lene Jorgensen et al.
EXPERT OPINION ON DRUG DELIVERY (2009)
Exploring protein fitness landscapes by directed evolution
Philip A. Romero et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
Protein Dynamism and Evolvability
Nobuhiko Tokuriki et al.
SCIENCE (2009)
mRNA display selection of a high-affinity, modification-specific phospho-IκBα-binding fibronectin
C. Anders Olson et al.
ACS CHEMICAL BIOLOGY (2008)
The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer
Sean P. Dineen et al.
BMC CANCER (2008)
The stability effects of protein mutations appear to be universally distributed
Nobuhiko Tokuriki et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Relative tolerance of mesostable and thermostable protein homologs to extensive mutation
Werner Besenmatter et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2007)
Effect of buffer species on the thermally induced aggregation of interferon-tau
Derrick S. Katayama et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro
Elena V. Getmanova et al.
CHEMISTRY & BIOLOGY (2006)
Protein stability promotes evolvability
JD Bloom et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two
MH Parker et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2005)
Stability improvement of antibodies for extracellular and intracellular applications:: CDR grafting to stable frameworks and structure-based framework engineering
S Ewert et al.
METHODS (2004)
Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms
B Chen et al.
PHARMACEUTICAL RESEARCH (2003)
The effects of arginine on refolding of aggregated proteins: not facilitate refolding, but suppress aggregation
T Arakawa et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
How do thermophilic proteins deal with heat?
S Kumar et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2001)
Share Paper
